Sulfinpyrazone has no effect on the insulin requirements of diabetics, nor does it affect the diabetic
control of patients taking glibenclamide (
glyburide).
Sulfinpyrazone reduces the clearance of
tolbutamide, but as yet there appear to be no case reports of this interaction.
Sulfinpyrazone modestly increased the AUC of
nateglinide, but this is unlikely to be clinically relevant.
No action needed.